Trials / Completed
CompletedNCT02292719
A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With or Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection or Genotype 3 HCV Infection With or Without Cirrhosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of Ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) with sofosbuvir (SOF) with or without ribavirin (RBV) in adults with Genotype 2 Chronic Hepatitis C Virus (HCV) infection or Genotype 3 HCV infection with or without Cirrhosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OBV/PTV/r | Tablet |
| DRUG | Sofosbuvir | Tablet |
| DRUG | Ribavirin (RBV) | Tablet |
Timeline
- Start date
- 2014-12-19
- Primary completion
- 2017-07-14
- Completion
- 2017-07-14
- First posted
- 2014-11-17
- Last updated
- 2021-07-12
- Results posted
- 2018-07-06
Source: ClinicalTrials.gov record NCT02292719. Inclusion in this directory is not an endorsement.